Recent advancements in the melanoma treatment paradigm have drastically improved outcomes and changed the diagnosis of metastatic melanoma from a horrible prognosis to a potentially curable one. DocWire News spoke to John Fruehauf, MD, field medical director at Evolent, about how new therapies have improved the landscape of metastatic melanoma care.
Melanoma News
Several Models Externally Validated for Sentinel Lymph Node Biopsy Positivity in Melanoma
WEDNESDAY, March 12, 2025 (HealthDay News) — In a review and meta-analysis published online March 12 in JAMA Dermatology, several risk prediction models are identified and externally validated for sentinel lymph node biopsy (SLNB) positivity in melanoma.
Real-World Data Shows Promise for Advanced Melanoma Patients
Hello. I’m Dr Maurie Markman, from City of Hope. I’d like to present what I consider to be very important and positive objective data regarding the impact that we are having on the management of cancer, in general, and advanced cancers in particular. The paper I’m referring to is entitled, “Long-term survival in patients with advanced melanoma,” published in JAMA Network Open.
SKYLINEDX ANNOUNCES NEW STUDY DEMONSTRATING ENHANCED RISK STRATIFICATION FOR SENTINEL LYMPH NODE BIOPSY IN HEAD AND NECK MELANOMA USING THE ADVANCED MERLIN CP-GEP TEST
ROTTERDAM, Netherlands and SAN DIEGO, March 12, 2025 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology and, inflammatory and infectious diseases, proudly announces the publication of a groundbreaking study titled “Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP)." [1] This study, led by Ani Pazhava, MD, and colleagues from the Mayo Clinic and University Hospitals Cleveland Medical Center and SkylineDx, highlights the potential of the Merlin test to refine clinical decision-making in head and neck melanoma patients.